Work

A phase I study of the mitochondrial metabolism inhibitor CPI-613 in combination with high-dose ara-C (HDAC) and mitoxantrone for relapsed or refractory acute myeloid leukemia (AML).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.7028

Authors: Timothy S. Pardee, Kristin Stadelman, Scott Isom, Leslie R. Ellis, Dmitriy P. Berenzon, Robin Harrelson, Megan Manuel, Sarah Dralle, Susan Lyerly, Bayard L. Powell

Institutions: Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2906837589

Cites:

Cited by: 1

Related to: 10